Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all

Documenti analoghi

• Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study
  di: Marshall, Alison D., et al.
  Pubblicazione: (2016)
• Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
  di: Al-Busafi, Said A., et al.
  Pubblicazione: (2017)
• Addressing disparities in care and research: New ideas for ensuring that all voices are heard
  di: Murphy, Carolann, et al.
  Pubblicazione: (2021)
• Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era
  di: Falade-Nwulia, Oluwaseun, et al.
  Pubblicazione: (2018)
• Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population
  di: Marcus, Julia L., et al.
  Pubblicazione: (2018)